Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, August 6 '25)

Image
By G.M.

 


    BMJ

  1. WISE J
    RFK Jr bans thiomersal from influenza vaccines in "safety" move.
    BMJ. 2025;390:r1576.
    PubMed        


    Epidemiol Infect

  2. KELLY GE, Petti S, Noah N
    Excess respiratory, circulatory, neoplasm, and other mortality rates during the Covid-19 pandemic in the EU and their implications.
    Epidemiol Infect. 2025;153:e86.
    PubMed         Abstract available


    Eur J Epidemiol

  3. ORTQVIST AK, Soderling J, Magnus MC, Urhoj SK, et al
    COVID-19 infection increases the risk of venous thromboembolism during pregnancy and the postpartum period.
    Eur J Epidemiol. 2025;40:779-788.
    PubMed         Abstract available

  4. BAUMKOTTER R, Yilmaz S, Chalabi J, Ten Cate V, et al
    Risk tools for predicting long-term sequelae based on symptom profiles after known and undetected SARS-CoV-2 infections in the population.
    Eur J Epidemiol. 2025;40:789-801.
    PubMed         Abstract available


    J Gen Virol

  5. CHAN JCM, Ching RHH, Kock HHM, Long T, et al
    Evaluation of pandemic potential of the genotype 4 (G4) swine influenza virus using ex vivo and in vitro cultures of the human respiratory tract.
    J Gen Virol. 2025;106:002133.
    PubMed         Abstract available


    J Immunol

  6. AGRAFIOTIS A, Kuhn R, Panetti C, Venerito M, et al
    Clonally expanded IgG, but not IgA, antibody-secreting cells preferentially target influenza nucleoprotein following homologous and heterologous infections.
    J Immunol. 2025 Jul 26:vkaf144. doi: 10.1093.
    PubMed         Abstract available


    J Infect Dis

  7. EPSI NJ, Chenoweth JG, Blair PW, Lindholm DA, et al
    Precision Symptom Phenotyping Identifies Early Clinical and Proteomic Predictors of Distinct COVID-19 Sequelae.
    J Infect Dis. 2025;232:39-49.
    PubMed         Abstract available

  8. ZHOU JR, Liao Y, Cao LQ, Ma R, et al
    Interleukin 6 Is Significantly Increased in Severe Pneumonia After Allo-Hematopoietic Stem Cell Transplantation and Might Induce Lung Injury via IL-6/sIL-6R/JAK1/STAT3 Pathway.
    J Infect Dis. 2025;232:113-126.
    PubMed         Abstract available

  9. CAILLAULT A, Softic L, Bay P, Ly A, et al
    Molecular Characterization of Respiratory Syncytial Virus Infections in Elderly Patients During the 2023-2024 Season in the Era of Nirsevimab Introduction.
    J Infect Dis. 2025;232:199-202.
    PubMed         Abstract available

  10. DE SCHRIJVER S, Vanhulle E, Ingenbleek A, Alexakis L, et al
    Epidemiological and Clinical Insights into Enterovirus Circulation in Europe, 2018-2023: A Multicenter Retrospective Surveillance Study.
    J Infect Dis. 2025;232:e104-e115.
    PubMed         Abstract available

  11. BEGIER E, Aliabadi N, Ramirez JA, McGeer A, et al
    Detection by Nasopharyngeal Swabs Alone Underestimates Respiratory Syncytial Virus-Related Hospitalization Incidence in Adults: The Multispecimen Study's Final Analysis.
    J Infect Dis. 2025;232:e126-e136.
    PubMed         Abstract available

  12. OBER V, Volk F, Sbierski-Kind J, Gruner E, et al
    Systemic and SARS-CoV-2 specific Immune Disturbances in Individuals With Post-COVID Syndrome.
    J Infect Dis. 2025;232:50-59.
    PubMed         Abstract available

  13. FITZPATRICK T, Buchan SA, Mahant S, Fu L, et al
    Pediatric Acute Respiratory Virus Hospitalizations: A Population-Based Cohort Study, 2017-2024.
    J Infect Dis. 2025;232:e137-e149.
    PubMed         Abstract available

  14. NAYAGAM SN, Coote W, Carroll MT, Toh ZQ, et al
    Differentiating SARS-CoV-2 antibody responses between infection and vaccination: challenges for epidemiological research.
    J Infect Dis. 2025 Jun 3:jiaf295. doi: 10.1093.
    PubMed        

  15. MATEJA A, Chu E, Murray TA, Bramante CT, et al
    The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death.
    J Infect Dis. 2025;232:60-68.
    PubMed         Abstract available


    JAMA

  16. UYEKI TM
    Pediatric Influenza-Associated Acute Necrotizing Encephalopathy-Gaps Need to Be Addressed.
    JAMA. 2025 Jul 30. doi: 10.1001/jama.2025.13003.
    PubMed        

  17. SILVERMAN A, Walsh R, Santoro JD, Thomas K, et al
    Influenza-Associated Acute Necrotizing Encephalopathy in US Children.
    JAMA. 2025 Jul 30:e2511534. doi: 10.1001/jama.2025.11534.
    PubMed         Abstract available


    Pediatrics


  18. Recommendations for Prevention and Control of Influenza in Children, 2025-2026: Technical Report.
    Pediatrics. 2025 Jul 28. doi: 10.1542/peds.2025-073622.
    PubMed         Abstract available


  19. Recommendations for Prevention and Control of Influenza in Children, 2025-2026: Policy Statement.
    Pediatrics. 2025 Jul 28. doi: 10.1542/peds.2025-073620.
    PubMed         Abstract available

  20. WANG D, Pham HT, Chai S, Hoover C, et al
    Characteristics of Children Aged 0 to 23 Months Hospitalized With Respiratory Syncytial Virus.
    Pediatrics. 2025;156:e2024069719.
    PubMed         Abstract available

  21. HARRIES MD, Saper JK, Macy ML, Martin-Gill C, et al
    Emergency Medical Services Responses to School-Based Medical Emergencies.
    Pediatrics. 2025;156:e2024068886.
    PubMed         Abstract available

  22. MARTON SA, Haq HA, Agathis NT, Swamy P, et al
    A 4-Year Residency Program in Pediatrics/Global Child Health.
    Pediatrics. 2025;156:e2024068761.
    PubMed         Abstract available

  23. AHMED MM, Wang Z, Joerger T, Michel J, et al
    Disparities in Nirsevimab Uptake Across a Pediatric Primary Care Network.
    Pediatrics. 2025;156:e2025070790.
    PubMed         Abstract available

  24. HSIAO A, Hansen J, Fireman B, Timbol J, et al
    Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants.
    Pediatrics. 2025 Jul 22:e2024069510. doi: 10.1542/peds.2024-069510.
    PubMed         Abstract available


    PLoS Comput Biol

  25. NGANDU NK, Fielding BC, van Heusden P, Mcinga K, et al
    Population-level toggling of T cell immune escape at human leukocyte antigen anchor residues in SARS-CoV-2 Spike proteins, in an ethnically diverse population region.
    PLoS Comput Biol. 2025;21:e1013261.
    PubMed         Abstract available


    PLoS One

  26. SAFTA C, Ray J, Bridgman W
    Detecting outbreaks using a spatial latent field.
    PLoS One. 2025;20:e0328770.
    PubMed         Abstract available

  27. AZAMI-AGHDASH S, Mohammaddokht S, Kashani M, Pourgholam N, et al
    Public education during epidemics of infectious diseases: A national mixed-method study with parallel convergent design in a low and middle-income country.
    PLoS One. 2025;20:e0328451.
    PubMed         Abstract available

  28. AZANGOU-KHYAVY M, Ghasemi E, Ebrahimi N, Rashidi MM, et al
    National and sub-national sero-epidemiology of immunoglobulin G against SARS-CoV-2 in Iran in 2021.
    PLoS One. 2025;20:e0313795.
    PubMed         Abstract available

  29. ALDILA D, Chavez JP, Nugroho B, Omede BI, et al
    Reassessment of public awareness and prevention strategies for HIV and COVID-19 co-infections through epidemic modeling.
    PLoS One. 2025;20:e0328488.
    PubMed         Abstract available

  30. TURNER S, Guevara Maldonado MR
    How can health systems sustain lessons drawn from emergency contexts? Evidence from Colombia.
    PLoS One. 2025;20:e0322486.
    PubMed         Abstract available

  31. PILKOVA A, Munk M, Kelebercova L
    Decoding corporate communication strategies: Analysing mandatory published information under Pillar 3 across turbulent periods with unsupervised machine learning.
    PLoS One. 2025;20:e0328841.
    PubMed         Abstract available

  32. PAJIC S, Buengeler C, Den Hartog DN, Hanke-Boer D, et al
    Prioritizing the bottom line over people in a crisis: How leader behavior affects employee psychological distress under economic threat.
    PLoS One. 2025;20:e0323415.
    PubMed         Abstract available

  33. FAILOC-ROJAS VE, Torres-Mera A, Leon-Figueroa DA, Lira D, et al
    Smartphone dependence, addiction, and insomnia among medical students during the COVID-19 pandemic.
    PLoS One. 2025;20:e0329495.
    PubMed         Abstract available

  34. HECKER I, Wallez S, Scarlett H, Ayuso-Mateos JL, et al
    Psychological distress and compliance with sanitary measures during the Covid-19 pandemic.
    PLoS One. 2025;20:e0317272.
    PubMed         Abstract available

  35. POCH-PAEZ J, Novoa-Medina Y, Montesdeoca-Melian A, Hernandez-Betancor A, et al
    Age-dependent ACE2/TMPRSS2 expression and SARS-CoV-2 household transmission in Gran Canaria.
    PLoS One. 2025;20:e0329229.
    PubMed         Abstract available

  36. MCTAGGART E, Megiddo I, Bowers J, Kleczkowski A, et al
    Sickness absence rates in NHS England staff during the COVID-19 pandemic: Insights from multivariate regression and time series modelling.
    PLoS One. 2025;20:e0323035.
    PubMed         Abstract available

  37. LI C, He Y, Pan X, Yin H, et al
    Viral etiology of severe acute respiratory infections in hospitalized patients, Shandong, China.
    PLoS One. 2025;20:e0328439.
    PubMed         Abstract available

  38. ENSHAEI N, Mohammadi A, Naderkhani F, Daneman N, et al
    Differentiation of COVID-19 from other types of viral pneumonia and severity scoring on baseline chest radiographs: Comparison of deep learning with multi-reader evaluation.
    PLoS One. 2025;20:e0328061.
    PubMed         Abstract available

  39. TOLLE H, Wachinger J, Castro MDM, Morales I, et al
    Implementation of Point-of-Care PCR-testing for the diagnosis of respiratory infections in vulnerable patient populations.
    PLoS One. 2025;20:e0307621.
    PubMed         Abstract available

  40. SULLIVAN JD, Casazza ML, Poulson RL, Matchett EL, et al
    Potential impacts of 2.3.4.4b highly pathogenic H5N1 avian influenza virus infection on Snow Goose (Anser caerulescens) movement ecology.
    PLoS One. 2025;20:e0328149.
    PubMed         Abstract available

  41. VIZGIRDA G, Underwood AP, Fahnoe U, Weis N, et al
    Spike substitutions E484D, P812R and Q954H mediate ACE2-independent entry of SARS-CoV-2 across different cell lines.
    PLoS One. 2025;20:e0326419.
    PubMed         Abstract available

  42. XU A, Liu Y, Li S, Zhan C, et al
    Global burden of major chronic respiratory diseases among older adults aged 55 and above from 1990 to 2021: Changes, challenges, and predictions amid the pandemic.
    PLoS One. 2025;20:e0329283.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  43. SAKURAI Y, Fujioka Y, Maishi N, Takeda R, et al
    SARS-CoV-2 uptake and inflammatory response in senescent endothelial cells are regulated by the BSG/VEGFR2 pathway.
    Proc Natl Acad Sci U S A. 2025;122:e2502724122.
    PubMed         Abstract available

  44. YEH KB, Bahnfleth WP, Bradforda E, Cardona C, et al
    Three things we can do now to reduce the risk of avian influenza spillovers.
    Proc Natl Acad Sci U S A. 2025;122:e2503565122.
    PubMed        

  45. LAHIRI H, Israeli E, Krugliak M, Basu K, et al
    A bacteria-based search for drugs against avian and swine flu yields a potent and resistance-resilient channel blocker.
    Proc Natl Acad Sci U S A. 2025;122:e2502240122.
    PubMed         Abstract available


    Vaccine

  46. RIZZO KR, Yen CJ, Quint J, Hoover C, et al
    Sociodemographic disparities in COVID-19 and RSV vaccine uptake among California adults >/=60 years old who received influenza vaccination.
    Vaccine. 2025;62:127535.
    PubMed         Abstract available

  47. OMOLE T, Weinberg AS, Azizad M, Greenberg D, et al
    A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older.
    Vaccine. 2025;62:127514.
    PubMed         Abstract available

  48. CUEVAS FI
    Commentary: Processes of pre-clinical and clinical vaccine development public data sharing within the NIAID collaborative influenza vaccine innovation centers (CIVICs).
    Vaccine. 2025;62:127547.
    PubMed         Abstract available


    Virology

  49. ZHANG MC, Wu H, Wang J, Lu M, et al
    Multi-level inhibition of SARS-CoV-2 invasion by cannabidiol and epigallocatechin gallate.
    Virology. 2025;610:110579.
    PubMed         Abstract available

  50. SMET M, Berkell M, Gorska A, Tacconelli E, et al
    Drivers of quasispecies development in SARS-CoV-2 and implications for emergent variants and COVID-19.
    Virology. 2025;610:110584.
    PubMed         Abstract available

  51. MOTHAE SA, Chiliza TE, Mvubu NE
    SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis.
    Virology. 2025;610:110607.
    PubMed         Abstract available

  52. FENG S, Huang M, Quan Y, Sun L, et al
    The spike 486 site is a key immune evasion point and a determinant of the immunogenicity of the RBD-dimer mRNA vaccine against SARS-CoV-2 variants.
    Virology. 2025;610:110612.
    PubMed         Abstract available

  53. STEGMANN KM, Dickmanns A, Fuchs HL, Scheibner D, et al
    Synergistic interference with SARS-CoV-2 replication by molnupiravir-derived N(4)-hydroxycytidine and inhibitors of CTP synthetase in cell culture.
    Virology. 2025;610:110598.
    PubMed         Abstract available

  54. SMAOUI F, Taktak A, Gargouri S, Chtourou A, et al
    Impact of the COVID-19 pandemic on the molecular epidemiology of respiratory rhinoviruses and enteroviruses in Tunisia.
    Virology. 2025;610:110624.
    PubMed         Abstract available

  55. FENG X, Yang X, Hu X, Liu Q, et al
    The combinatorial activities of oseltamivir and molnupiravir against influenza virus infections in vitro and in vivo.
    Virology. 2025;611:110642.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »